eligibility_summary
Eligibility: Inoperable advanced solid tumors with progression after/declined standard therapy (≥2 wks since last treatment), ECOG 0–2, life expectancy ≥3 mo, negative HIV/HBV/HCV/TP, adequate organ function/blood counts, negative pregnancy test/contraception. Exclude: pregnancy/lactation, brain mets, recent steroids/immunotherapy/other trials, autoimmune or immunodeficiency, serious CNS disorder, substance abuse, unstable systemic disease or MI <1 yr, other cancers <5 yrs (except cured/skin).
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Trial NCT05749627 tests two personalized immunotherapies for advanced solid tumors: 1) Neoantigen peptide vaccine (synthetic, patient-specific peptide mix). 2) Neoantigen-based dendritic cell (DC) vaccine (autologous DCs ex vivo loaded with those peptides). Mechanism: bioinformatically identified mutation-derived peptides are presented via HLA class I/II to prime and expand tumor-specific T cells, eliciting CD8+ cytotoxic and CD4+ helper responses and immunologic memory. Targets: tumor neoantigens, dendritic cells, CD8+ and CD4+ T cells, pathways include MHC I/II antigen presentation, TCR signaling, clonal expansion, and cytotoxic/IFN-γ effector programs.